--- title: "Tenaya Therapeutics (TNYA) news: offering and Nasdaq notice" url: "https://aibio.space/companies/tenaya-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TNYA offering and Nasdaq notice news: Tenaya Therapeutics prices $52.5 million offering of 75,000,000 units at $0.70. Tenaya Therapeutics, Inc." --- TNYA Tenaya Therapeutics, Inc. NASDAQ · United States # Tenaya Therapeutics (TNYA) news TNYA offering and Nasdaq notice news Listings · 2026-01-30 ## [Tenaya Therapeutics gets Nasdaq minimum bid price notice, has until July 27, 2026](https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-minimum-bid-price-notice-has-until/) Nasdaq told Tenaya Therapeutics on January 28, 2026 that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 27, 2026 to regain compliance, and an 8-K filed January 30 also adds 2,161,000 shares to its inducement equity plan. ## Latest Tenaya Therapeutics news 1. 2025-04-18 Listings [Tenaya Therapeutics gets Nasdaq notice for trading below $1.00](https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-notice-trading-below-1-00/) Tenaya has until October 13, 2025 to regain compliance, and may get another 180 days if it moves to the Nasdaq Capital Market. 2. 2025-03-03 Financings [Tenaya Therapeutics prices $52.5 million offering of 75,000,000 units at $0.70](https://aibio.space/news/tenaya-therapeutics-prices-52-5-million-offering-75-000-000-units-0-70/) Tenaya priced 75,000,000 units at $0.70 for about $52.5 million, with two warrant series attached to each unit. Its lead gene therapies are in early trials with only a few patients dosed, and the stock's last reported sale price on the pricing day was $0.9469. ## Tenaya Therapeutics at a glance - **Ticker**: TNYA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $78.1 million ### Related companies - [Theriva Biologics](https://aibio.space/companies/theriva-biologics/) AMEX: TOVX - [Acura Pharmaceuticals](https://aibio.space/companies/acura-pharmaceuticals/) OTC: ACUR - [Evelo Biosciences](https://aibio.space/companies/evelo-biosciences/) OTC: EVLO - [Cytokinetics](https://aibio.space/companies/cytokinetics/) NASDAQ: CYTK - [Talphera](https://aibio.space/companies/talphera/) NASDAQ: TLPH - [Ironwood Pharmaceuticals](https://aibio.space/companies/ironwood-pharmaceuticals/) NASDAQ: IRWD - [Abeona Therapeutics](https://aibio.space/companies/abeona-therapeutics/) NASDAQ: ABEO - [Karyopharm Therapeutics](https://aibio.space/companies/karyopharm-therapeutics/) NASDAQ: KPTI ### Also on NASDAQ - [DarioHealth](https://aibio.space/companies/dariohealth/) DRIO - [Rapport Therapeutics](https://aibio.space/companies/rapport-therapeutics/) RAPP - [Gain Therapeutics](https://aibio.space/companies/gain-therapeutics/) GANX - [Axogen](https://aibio.space/companies/axogen/) AXGN - [BIODESIX INC](https://aibio.space/companies/biodesix/) BDSX - [Pharvaris](https://aibio.space/companies/pharvaris-n-v/) PHVS ## Tenaya Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$68.6 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | [$86.7 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | | Net income (loss) | [-$90.6 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | [-$111.1 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | | Cash from operations | [-$68.3 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | [-$90.5 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | | Cash and equivalents | [$100.5 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526335140/) | [$4.3 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | | Short-term investments | | [$57.1 million](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102252/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $78.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Tenaya Therapeutics Has Tenaya Therapeutics raised money recently? Our latest story on this, dated Mar 3, 2025: "Tenaya Therapeutics prices $52.5 million offering of 75,000,000 units at $0.70". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tenaya-therapeutics-prices-52-5-million-offering-75-000-000-units-0-70/). Has Tenaya Therapeutics received a Nasdaq deficiency notice? Our latest story on this, dated Apr 18, 2025: "Tenaya Therapeutics gets Nasdaq notice for trading below $1.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-notice-trading-below-1-00/). What is the ticker symbol of Tenaya Therapeutics? Tenaya Therapeutics, Inc. trades under the ticker TNYA on NASDAQ. Where is Tenaya Therapeutics listed? Tenaya Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Tenaya Therapeutics? The SEC Central Index Key (CIK) for Tenaya Therapeutics, Inc. is 1858848. Its filings are on SEC EDGAR. How many shares does Tenaya Therapeutics have outstanding? 224,230,012 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Tenaya Therapeutics listed under? Our directory records Tenaya Therapeutics, Inc. under United States. What does Tenaya Therapeutics do? Our directory classifies Tenaya Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Tenaya Therapeutics? The ISIN recorded for Tenaya Therapeutics, Inc. is US87990A1060. Does aibio.space cover Tenaya Therapeutics? aibio.space lists Tenaya Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Tenaya Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Tenaya Therapeutics profitable? Tenaya Therapeutics, Inc. reported a net loss of $90.6 million for the fiscal year ended Dec 31, 2025, and used $68.3 million of cash in operations, per its annual report to the SEC. How much does Tenaya Therapeutics spend on research and development? $68.6 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Tenaya Therapeutics have? $78.1 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Tenaya Therapeutics (TNYA) stock news? Our latest story on Tenaya Therapeutics, dated Jan 30, 2026: "Tenaya Therapeutics gets Nasdaq minimum bid price notice, has until July 27, 2026". Nasdaq told Tenaya Therapeutics on January 28, 2026 that its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until July 27, 2026 to regain compliance, and an 8-K filed January 30 also adds 2,161,000 shares to its inducement equity plan. [Source](https://aibio.space/news/tenaya-therapeutics-gets-nasdaq-minimum-bid-price-notice-has-until/). ## Investor discussion: Tenaya Therapeutics Members talk about Tenaya Therapeutics (TNYA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Tenaya Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-10-23 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1858848/000119312526430591/tnya-20261023.htm) 2. 2026-10-13 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1858848/000119312526420540/tnya-20261012.htm) 3. 2026-07-02 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02). [Source](https://www.sec.gov/Archives/edgar/data/1858848/000119312526294879/tnya-20260629.htm) 4. 2026-01-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1858848/000119312526032017/tnya-20260126.htm) 5. 2025-12-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1858848/000119312525316104/d61744d424b5.htm) 6. 2025-04-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1858848/000095017025055927/tnya-20250415.htm) 7. 2025-03-28 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05). [Source](https://www.sec.gov/Archives/edgar/data/1858848/000119312525067071/d660778d8k.htm) 8. 2025-03-03 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1858848/000119312525044134/d868429d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TNYA on TradingView](https://www.tradingview.com/symbols/NASDAQ-TNYA/). ## SEC filings and registration - **SEC name**: Tenaya Therapeutics, Inc. - **CIK**: 1858848 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: TNYA (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company
Emerging growth company - **Business address**: 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 415-865-2066 - **Shares outstanding**: 224,230,012 as of 2026-07-30 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1858848/000119312526335140/tnya-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1858848/000119312526335098/tnya-20260805.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1858848/000119312526294879/tnya-20260629.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1858848/000119312526286957/tnya-20260629.htm) filed 2026-06-29 - [8-K](https://www.sec.gov/Archives/edgar/data/1858848/000119312526248680/tnya-20260527.htm) filed 2026-05-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1858848/000119312526209084/tnya-20260331.htm) filed 2026-05-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1858848/000119312526208975/tnya-20260506.htm) filed 2026-05-06 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1858848/000119312526158079/tnya-20260415.htm) filed 2026-04-16 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001858848), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Tenaya Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TNYA, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Tenaya Therapeutics, Inc. - **Ticker**: TNYA - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US87990A1060 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TNYA/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tenaya-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tenaya Therapeutics (TNYA) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/tenaya-therapeutics/